Literature DB >> 22913703

Complete and partial responses of the TEMPI syndrome to bortezomib.

Wilfried Schroyens, Casey O'Connell, David B Sykes.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22913703     DOI: 10.1056/NEJMc1205806

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Long-term complete clinical and hematological responses of the TEMPI syndrome after autologous stem cell transplantation.

Authors:  S S Kenderian; F G Rosado; D B Sykes; J D Hoyer; M Q Lacy
Journal:  Leukemia       Date:  2015-10-26       Impact factor: 11.528

Review 2.  TEMPI Syndrome: Update on Clinical Features, Management, and Pathogenesis.

Authors:  Jian Xu; Wenqi Liu; Fengjuan Fan; Bo Zhang; Fei Zhao; Yu Hu; Chunyan Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-19       Impact factor: 6.055

3.  Bone marrow findings of the newly described TEMPI syndrome: when erythrocytosis and plasma cell dyscrasia coexist.

Authors:  Flavia G Rosado; Jennifer L Oliveira; Aliya R Sohani; Wilfried Schroyens; David B Sykes; Saad S Kenderian; Martha Q Lacy; Robert A Kyle; James D Hoyer
Journal:  Mod Pathol       Date:  2014-09-12       Impact factor: 7.842

Review 4.  Diagnosis and management of monoclonal gammopathy of clinical significance.

Authors:  Hyungwoo Cho
Journal:  Blood Res       Date:  2022-04-30

5.  Case report: a 37-year-old male with telangiectasias, polycythemia vera, perinephric fluid collections, and intrapulmonary shunting.

Authors:  Javed Khan; David B Sykes
Journal:  BMC Hematol       Date:  2014-07-22

6.  Case Report: TEMPI syndrome: Report of three cases and treatment follow-up.

Authors:  Zhuo-Fan Xu; Jing Ruan; Long Chang; Sijin Wu; Jinkai Lin; Wei Wang; XinXin Cao; Lu Zhang; Jian Li; Daobin Zhou; Wei Zhang
Journal:  Front Oncol       Date:  2022-08-03       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.